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Abstract 
Context: In older adults, loss of mobility due to sarcopenia is exacerbated in 
men with low serum T. T replacement therapy is known to increase muscle 
mass and strength, but the effect of weekly (WK) vs monthly (MO) 
administration on specific fiber types is unknown. 
Objective: To determine the efficacy of WK vs MO T replacement on the size 
and functional capacity of individual fast and slow skeletal muscle fiber types. 
Design, Setting, and Patients: 
Subjects were randomized into a 5-month, double-blind, placebo-controlled 
trial. All subjects (ages, 61–71 y) were community-dwelling men who had T 
levels < 500 ng/dL. 
Intervention: Subjects were dosed weekly for 5 months, receiving 
continuous T (WK, n = 5; 100 mg T enanthate, im injection), monthly cycled 
T (MO, n = 7; alternating months of T and placebo), or placebo (n = 7). 
Muscle biopsies of the vastus lateralis were obtained before and after 
treatment. 
Main Outcome Measures: Main outcomes for individual slow and fast fibers 
included fiber diameter, peak force (P0), rate of tension development, 
maximal shortening velocity, peak power, and Ca2+ sensitivity. 
Results: Both treatments increased fiber diameter and peak power, with WK 
treatment 5-fold more effective than MO in increasing type I fiber P0. WK 
effects on fiber diameter and force were 1.5-fold higher in slow fibers 
compared to fast fibers. In fast type II fibers, diameter and P0 increased 
similarly between treatments. The increased power was entirely due to 
increased fiber size and force. 
Conclusions: In conclusion, T replacement effects were fiber-type 
dependent, restricted to increases in cell size, P0, and peak power, and 
dependent on the paradigm selected (WK vs MO). 
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The loss of muscle mass and strength with age can greatly limit 
the ability of older adults to maintain normal daily activities and 
physical function.1,–4 This problem is exacerbated in hypogonadal men 
with low T.5 T replacement therapy has been shown to protect against 
losses in muscle mass and strength by increasing muscle protein 
synthesis and decreasing protein degradation.5,6 The gains observed 
with T treatment are both age- and dose-dependent, with greater 
effects typically seen in younger compared to older men.5,7 Ferrando et 
al6 found that chronic T administration increased lean body mass and 
strength in older men and, in the fasted state, stimulated reutilization 
of intracellular amino acids produced during protein breakdown. The 
observed decrease in protein breakdown in the T-treated group is 
important because an age-associated increase in skeletal muscle 
proteolysis is thought to contribute to the sarcopenia experienced by 
older adults.8 
T administration, depending upon the dose and administration 
frequency, can be associated with adverse side effects including an 
increased hemoglobin and hematocrit and decreased high-density 
lipoprotein cholesterol.9 Bhasin et al9 studied the dose dependency of T 
therapy on gains in muscle strength and the severity of adverse effects 
and found both to increase with the dose. They concluded that the 
best trade-off was achieved with an intermediate T dose of 125 mg 
weekly injections.9 Besides dose, the type of T administered and the 
duration of T administration may have implications on the functional 
responses in younger and older adults. The hormone-induced increase 
in the anabolic response may decrease with the duration of 
administration due to a return of the androgen receptor expression to 
pretreatment values.10 To address both the adverse effects and 
diminishing anabolic response of prolonged T administration, Sheffield-
Moore et al11 studied a monthly cycled T regimen that used half the 
dose of the standard continuous therapy. They alternated months of T 
and placebo (PL) treatment for a 5-month period and compared the 
results with a group receiving standard continuous therapy. Despite 
declining serum T levels in the cycled months of PL injection, muscle 
strength, muscle protein synthesis, and lean body mass increased, and 
the percentage of body fat was reduced after 5 months of treatment in 
both groups. The rate of increase in lean body mass and extensor leg 
strength was less in the group receiving T in a cycled fashion, but both 
groups reached similar levels by 5 months. 
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To date, little is known about the specific effects of T 
replacement (either WK or MO) on the individual fast and slow fiber 
types of limb skeletal muscle. Sinha-Hikim et al12 found significant 
increases in vastus lateralis volume and slow type I and fast type II 
fiber area, but only at serum T levels > 1000 ng/dL, which represent 
levels on the upper end of normal (or slightly above) and are much 
higher than seen in this study. Increases in leg and arm muscle 
strength suggest an improved fiber function, but the extent to which 
the adaptations are specific to a given fiber type are unknown. 
Additionally, the relative importance of changes in force and velocity in 
increasing peak power and whether or not there are changes in 
myofilament Ca2+ sensitivity that contribute to functional improvement 
are also unexplored. Thus, the goal of this study was to answer these 
questions using muscle biopsies obtained from the subject population 
previously reported on by Sheffield-Moore et al.11 
Subjects and Methods 
Ethical approval 
This study was approved by the University of Texas Medical 
Branch (UTMB) and Marquette University Institutional Review Boards 
and complied with the Declaration of Helsinki. Written informed 
consent was obtained from all subjects. 
Subjects 
The subjects were a subset of a larger study of 24 individuals 
recruited by Sheffield-Moore et al.11 From that subject population, we 
received muscle biopsies from 19 healthy, community-dwelling older 
men (ages, 60–85 y). In the case of the subjects not studied, there 
was insufficient sample size. All subjects had endogenous levels of 
serum total T in the lower half of the normal range (between 204 and 
485 ng/dL). The recruitment process, preselection battery of tests, and 
exclusion criteria were exactly as described by Sheffield-Moore et al.11 
Study design 
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The study design was as described previously and reviewed 
here.11 We conducted a randomized, double-blinded, PL-controlled trial 
in older men to test whether T administered either continuously or 
cyclically improves contractile function of single slow and fast fibers 
isolated from the vastus lateralis muscle of older men. All men were 
randomized by the UTMB Investigational Drug Service pharmacist into 
the following groups: 1) weekly T (WK; n = 8; 100 mg T-enanthate im 
per week); 2) monthly T (MO; n = 8; alternating months of 100 mg T-
enanthate and PL per week); or 3) PL (n = 8). Serum T levels were 
measured at the nadir before the next injection using the Bayer Advia 
Centaur immunoassay (Bayer Corp) as described in the Supplemental 
Data. The subset of subjects (ages, 61–71 y) for these data totaled 5, 
7, and 7 for the WK, MO, and PL groups, respectively. Subjects were 
dosed weekly for 5 months by a research nurse at the UTMB Institute 
for Translational Science Clinical Research Center.11 
Cell studies 
Muscle biopsies 
Before and at the end of the 5 months of T therapy, muscle 
biopsies (∼100–200 mg) were taken from the vastus lateralis 
approximately 15–20 cm above the knee.11 The portion used for the 
present experiment was immediately placed in cold skinning solution 
(composition in mm: 125 K propionate, 20 imidazole [pH 7.0], 2 
EGTA, 4 ATP, and 1 MgCl2, and 50% glycerol vol/vol), and shipped 
overnight at 4°C to Marquette University, where it was stored at 
−20°C. All of the fiber studies were conducted within 4 weeks of the 
biopsy. 
Solutions and single-fiber isolation procedures 
The relaxing (pCa 9.0, where pCa is the negative log of the Ca2+ 
concentration) and activating (pCa 4.5) solutions and fiber isolation 
procedure were as previously described.13,–15 The total and free 
concentrations of each metal, ligand, and metal ligand complex in the 
solutions were calculated using an iterative computer program with 
stability constants adjusted for temperature, pH, and ionic 
strength.16,17 
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On the day of an experiment, a single fiber segment was 
isolated from the muscle bundle, submerged in relaxing solution, and 
mounted between a force transducer and a position motor as 
previously described.13,14 The fiber was viewed at ×800, sarcomere 
length was adjusted to 2.5 μm, and fiber length (FL) and diameter 
were determined.15 Fiber cross-sectional area (CSA) was calculated 
from the diameter.18 
Determination of peak force (P0), rate of tension 
development (ktr), maximal unloaded shortening 
velocity (V0), and force-velocity relationship 
Fibers were maximally activated in pCa 4.5 solution (15°C), and 
peak force (P0) was recorded. Fiber V0 (FL s−1) was measured by the 
slack test.14 
In slow fibers, we determined the rate constant for force 
redevelopment (ktr) by generating a rapid slack (20% of FL) and re-
extension of a fully activated fiber.19,20 The redevelopment of tension 
was fit by a single exponential, and ktr was determined. 
The force-velocity relationship was determined from a series of 
isotonic releases as described previously.13 Vmax was defined as the 
intercept of the force-velocity curve with the velocity axis, and peak 
absolute power was calculated from P0, Vmax, and a/P0 where the latter 
parameter specifies the curvature of the force-velocity relation.13 For 
graphical purposes, composite force-velocity-power relationships were 
plotted using the mean parameters.13 
Determination of the pCa-force relationship and fiber stiffness 
A separate group of fibers was used to determine the pCa-force 
relationship, which reflects the myofibril Ca2+ sensitivity. These 
experiments were conducted exactly as described by Widrick et al.13 
Hill plots were used to determine the minimal Ca2+ required for force 
development (activation threshold) and that required for 50% 
activation (pCa50).13 To determine fiber stiffness, fibers were vibrated 
first in relaxing solution (pCa 9) and then at the peak of the pCa 4.5 
activation with a sinusoidal length change of 0.05% of FL and 1.5 
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kHz.15 Changes in length (Δlength) and force (Δforce) were used to 
calculate peak elastic modulus (E0) as follows: {E0 = [Δforce in 
activating solution − Δforce in relaxing solution/(Δlength)] (FL/CSA)}. 
Fiber type identification 
After the contractile measurements, fibers were solubilized in 10 μL of 
1% SDS sample buffer and stored at −80°C. Fibers were identified as 
fast type II or slow type I based on their myosin heavy chain isoform 
determined from 5% PAGE.14,21 
Statistical analysis 
Pre- and post-treatment means were analyzed using a two-tailed t 
test. Statistical significance was accepted at P < .05. 
Results 
Cell diameter and P0 
The effects of WK and MO T therapy on fiber diameter, P0, and 
V0 for slow type I and fast type II fibers are shown in Table 1. Before 
treatment, the MO group had significantly smaller fiber diameters for 
both slow type I and fast type II fiber than the PL group. The WK and 
MO treatments had differential effects, with WK significantly increasing 
type I fiber diameter and MO significantly increasing type II fiber 
diameter (Table 1). Although not significant, there was a trend (P 
< .1) for MO to increase type I fiber diameter. The PL group showed a 
decreased type II fiber diameter, which resulted in an increased 
specific force (Table 1). 
Table 1. Type I and II Fiber Diameter, P0, and V0 With Weekly and Monthly T 
VL Muscle Diameter, μm P0, mN P0, kN/m2 V0, FL/s 
Type I 
    
    PL 
    
        Pre 101 ± 2 (54) 0.89 ± 0.04 (53) 111 ± 3 (53) 0.71 ± 0.04 (53) 
        Post 99 ± 2 (75) 0.88 ± 0.04 (71) 112 ± 3 (71) 0.66 ± 0.02 (73) 
        % Difference −3 −1 1 −7 
    Weekly 
    
        Pre 102 ± 2 (60) 0.87 ± 0.03 (58) 106 ± 2 (58) 0.66 ± 0.03 (58) 
        Post 118 ± 4 (48)a 1.25 ± 0.08 (48)a 111 ± 2 (48) 0.64 ± 0.02 (48) 
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VL Muscle Diameter, μm P0, mN P0, kN/m2 V0, FL/s 
        % Difference 16 44 4 −3 
    Monthly 
    
        Pre 90 ± 2 (70)b 0.76 ± 0.02 (70)b 118 ± 2 (70) 0.66 ± 0.02 (70) 
        Post 94 ± 2 (66)c 0.82 ± 0.03 (65)a 116 ± 2 (65) 0.68 ± 0.02 (65) 
        % Difference 5 8 −2 3 
Type II 
    
    PL 
    
        Pre 96 ± 2 (71) 0.89 ± 0.04 (67) 128 ± 4 (67) 2.96 ± 0.14 (66) 
        Post 86 ± 2 (60)a 0.83 ± 0.03 (60) 143 ± 4 (60)a 2.72 ± 0.21 (59) 
        % Difference −10 −7 11 −8 
    Weekly 
    
        Pre 96 ± 3 (22) 0.98 ± 0.07 (21) 130 ± 5 (21) 2.79 ± 0.25 (21) 
        Post 106 ± 4 (44) 1.26 ± 0.09 (44)a 141 ± 3 (44)a 2.47 ± 0.11 (44) 
        % Difference 10 29 9 −11 
    Monthly 
    
        Pre 85 ± 2 (49)b 0.81 ± 0.03 (46) 144 ± 3 (46)b 2.44 ± 0.08 (46)b 
        Post 93 ± 2 (39)a 0.99 ± 0.03 (37)a 144 ± 3 (37) 2.51 ± 0.14 (37) 
        % Difference 9 22 0 3 
Abbreviation: VL, vastus lateralis muscle. Values represent means ± SE with the 
number of fibers studied in parentheses. The weekly group received T weekly for 5 
months; the monthly group received T weekly during months 1, 3, and 5. 
aSignificant difference (P < .05) between pre and post mean for a given group. 
bSignificant difference (P < .05) between PL pre mean and treatment group pre mean. 
cSignificant difference (P < .10) between pre and post mean for a given group. 
 
For the type I fiber, both treatments increased the absolute P0 
(millinewtons [mN]), but the magnitude of the effect was considerably 
greater with WK (44% increase) vs MO (8% increase) (Table 1). The 
increased type I fiber force appears primarily to be due to the increase 
in fiber size because the specific force (kilonewtons [kN]/m2) was not 
altered by either treatment. Similar results were observed for the type 
II fiber, except the percentage increase in absolute P0 was of the same 
magnitude with both treatments, and specific force significantly 
increased with WK (Table 1). 
V0, ktr, and peak power 
For both fiber types, the V0 was unaltered by WK or MO (Table 
1), and the type I fiber ktr was also unaffected by the treatments, with 
mean values ranging from 1.25 ± 0.03 to 1.29 ± 0.03−s for the three 
groups. Although there was no change in V0, type I fiber peak power 
significantly increased in the WK and MO groups (Figure 1 and 
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Supplemental Table 1), and like force, the increase was greater with 
WK (41 vs 13%). For the type II fiber, there was a trend (P < .1) for 
both treatments to increase peak power (Figure 1 and Supplemental 
Table 1). The curvature of the force-velocity relationship was unaltered 
by the treatments, except for type II fibers where WK significantly (P 
< .05) reduced the curvature as reflected by an increased a/P0 ratio 
(0.072 ± 0.004 vs 0.081 ± 0.004). There were no changes in relative 
peak power (Supplemental Table 1), suggesting that the increase in 
absolute peak power is primarily due to a T-induced increase in fiber 
size. Figure 1 shows that power increased with both treatment 
paradigms across the entire force-power spectrum from very light to 
heavy loads, and across this range the increase was greater with WK 
compared to MO. 
 
Figure 1. Force-power relationships for PL and treatment groups. Continuous lines 
represent the pretreatment and dashed lines represent the post-treatment force-
power relationships for type I and type II fibers for PL and weekly and monthly 
treatment groups. 
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E0 and the P0/E0 ratio 
The E0, a reflection of the number of attached cross-bridges per 
CSA, was not significantly altered by either paradigm in type I (Figure 
2A) or type II fibers. For both groups combined, the mean stiffness 
(E0) was 2.19 ± 0.04 (n = 160) and 1.83 ± 0.04 (n = 44) for type I 
and II fibers, respectively. The lack of change in E0 with treatment 
suggests that neither WK nor MO affected the number of cross-bridges 
per CSA. The P0/E0 ratio, an indicator of the force per cross-bridge, 
was also unaltered except for the type I fibers where WK significantly 
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increased the ratio (Figure 2B).
 
Figure 2. Stiffness and force stiffness ratio. A, Mean type I fiber stiffness before (E0-
WK-Pre) and after (E0-WK-Post) weekly T treatment, and before (E0-MO-Pre) and after 
(E0-MO-Post) monthly T treatment. B, Mean force/stiffness ratio before (P0/E0-WK-Pre) 
and after (P0/E0-WK-Post) weekly T treatment, and before (P0/E0-MO-Pre) and after 
(P0/E0-MO-Post) monthly T treatment. *, Significant difference (P < .05) between pre 
and post mean for a given group. 
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Calcium sensitivity 
The WK and MO treatments had no effect on calcium sensitivity 
of the contractile filaments, as reflected by no change in the Ca2+ 
required to initiate contraction (activation threshold) or that needed 
for one-half maximal activation (pCa50). Additionally, the slope of the 
force-pCa relationship (Hill plot) below (N2) and above (N1) one-half 
maximal activation was unaltered (Supplemental Table 2). 
Comparison of T administration to fiber size and force 
outcomes 
From Table 1, it is clear that the primary effect of T therapy 
administered either continuously or in a cycled fashion was to increase 
fiber size and absolute force. To further assess this aspect, we graphed 
the relationship between fiber diameter and peak absolute force for 
each individual for type I (Figures 3 and 4) and type II (Supplemental 
Figures 1 and 2) fibers. As is often seen in the clinical realm, some 
men respond to a given dose and others do not, thus requiring dose 
adjustment to manage symptoms. As such, in this study, where dose 
adjustment was not performed as done clinically, certain men 
responded to their administration paradigm (WK or MO), and others 
did not. If subjects showed a significant increase in fiber force in both 
slow and fast fibers, they were classified as responders (Tables 2 and 
3, Figures 3 and 4 and Supplemental Figures 1 and 2). With WK 
therapy, subjects WK 1 and WK 2 both showed an increase in type I 
and type II fiber diameter and force (post-treatment fibers all shifted 
to the right and up on the plot; Figure 3 and Supplemental Figure 1). 
WK 3 was a responder who showed an increased force with no change 
in fiber diameter (Figure 3). With MO treatment, subjects MO 1 and 
MO 2 (Figure 4 and Supplemental Figure 2) responded similarly to 
subjects WK 1 and WK 2. Also, with MO therapy we observed two 
subjects (MO 3 and MO 4) who were partial responders showing 
significant increases in fast type II fiber P0 but no change in the slow 
type I fiber type. 
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Figure 3. Relationship between type I fiber diameter and peak Ca2+-activated force 
(P0) for weekly T (WK) treatment. Each symbol represents the results of a single 
vastus lateralis type I fiber for each subject where open squares are pretreatment 
fibers and filled squares are post-treatment fibers. The gray shaded triangle and gray 
shaded circle are the mean pre- and post-treatment values for the PL group, 
respectively. 
 
 
Figure 4. Relationship between type I fiber diameter and peak Ca2+-activated force 
(P0) for monthly T (MO) treatment. Each symbol represents the results of a single 
vastus lateralis type I fiber for each subject where open squares are pretreatment 
fibers and filled squares are post-treatment fibers. The gray shaded triangle and gray 
shaded circle are the mean pre- and post-treatment values for the PL group, 
respectively. The asterisk indicates that subject MO 3, although a nonresponder for 
the slow type I fiber, was a responder for the fast type II fiber. 
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Table 2. Age, Leg Strength, and Plasma T for PL, MO, and WK Groups 
Groups Age, 
y 
Leg Extension 
Strength, kg 
 
Leg Curl 
Strength, kg 
 
T, ng/dL 
 
Pre Post Pre Post Pre Post 
PL 65 ± 
3 
70 ± 21 74 ± 13 46 ± 6 48 ± 7 344 ± 
85 
343 ± 73 
Monthly 
(MO) 
72 ± 
8 
73 ± 15 85 ± 19 44 ± 7 50 ± 11a 357 ± 
103 
665 ± 
25a,+ 
Weekly 
(WK) 
73 ± 
8 
66 ± 16 83 ± 17a 40 ± 9 51 ± 12a 341 ± 
85 
659 ± 
282a,+ 
Values are expressed as means ± SD. WK group received 100 mg T-enanthate weekly 
throughout the 5-month study; MO group received 100 mg T-enanthate weekly in 
alternating months. 
aPost value significantly different from pre value, P ≤ .05. 
+Post value significantly different from PL post value, P < .05. 
 
Table 3. Leg Strength, Type I Fiber P0, and Plasma T of Individual Subjects 
Individuals Leg Extension 
Strength, kg 
 
Type I Fiber P0, 
mN 
 
T, ng/dL 
 
Pre Post Pre Post Pre Ave 1–5 
Mo 
Highest 
WK 1 
(Responder) 
79.4 86.2 1.01 2.12a 261 503 553 
WK 2 
(Responder) 
41.2 60.8 0.65 1.22a 204 613 818 
WK 3 
(Responder) 
72.6 81.6 0.76 0.93a 356 595 782 
WK 4 (NonRes) 77.1 86.2 0.92 0.98 401 894 952 
WK 5 (NonRes) 74.8 97.5 0.86 0.71 280 386 492 
MO 1 
(Responder) 
77.1 81.6 0.71 0.94a 277 365 584 
MO 2 
(Responder) 
74.8 72.6 0.69 0.96a 485 473 669 
MO 3 (PartRes) 54.4 61.2 0.98 0.86 260 674 985 
MO 4 (PartRes) 77.1 - 0.68 0.63 275 460 682 
MO 5 (NonRes) 104.3 113.4 0.81 0.77 409 459 598 
MO 6 (NonRes) 61.2 93.0 0.83 0.83 456 500 642 
MO 7 (NonRes) 68.0 68.0 0.62 0.64 241 384 617 
PL 1 90.7 74.8 1.03 1.05 379 382 463 
PL 2 56.7 63.5 - 0.77 255 253 318 
PL 3 113.4 95.2 0.92 1.24a 428 388 527 
PL 4 59.0 59.0 1.01 0.73a 444 387 444 
PL 5 68.0 81.6 1.08 0.63a 417 423 470 
PL 6 63.5 68.0 0.72 0.65 270 275 331 
PL 7 59.0 81.6 0.56 0.48 226 206 226 
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Abbreviations: NonRes, non-responder; PartRes, partial responder to T treatments; 
WK, received 100 mg T-enanthate weekly throughout the 5-month study; MO, 
received 100 mg T-enanthate weekly in alternating months; Ave 1–5 Mo, the mean T 
over the study calculated from each months' T. 
aPost value significantly different from pre value, P ≤ .05. 
Table 2 shows the average leg strength (extension and flexion) 
as well as serum T levels before and after T therapy for all 24 subjects. 
Before treatment, all subjects participating in this study (7 PL, 5 WK, 
and 7 MO) had circulating total T concentrations in the lower half of 
the normal range (333 ± 21 ng/dL), and the mean values stayed low 
in the PL group (284 ± 24 ng/dL) and cycled up and down in the MO 
group with a 5-month value of 474 ± 38 ng/dL, whereas in the WK 
group, T increased in the first month and remained high with 598 ± 84 
ng/dL at 5 months. Individual changes in T for the WK, MO, and PL 
subjects are shown in Table 2. The subjects with the greatest cellular 
response in the WK group started with low serum T that increased with 
treatment to above 500 ng/dL for both the average and peak values 
(subjects WK 1 and WK 2; Table 2). Non-responders either failed to 
show an increase in serum T above 500 ng/dL (subject WK 5) or had 
relatively high pretreatment T levels (subject WK 4). 
Discussion 
The use of T to treat adult males with serum T levels in the 
lower half of the normal range has been shown to improve muscle 
strength, but the ideal treatment paradigm and the selective effects on 
fast and slow fiber types are unknown.10,–12 A novel finding of this 
study is that P0 and peak power of the slow type I and fast type II 
fibers significantly increase in response to both continuous weekly 
administration of T for 5 months (WK) and monthly administration 
(MO) where T is administered weekly in months 1, 3, and 5 with PL 
injections in months 2 and 4. 
Fiber type differences with T therapy were observed with the 
WK paradigm to be 5-fold more effective than MO in increasing the 
slow type I fiber P0, whereas with the fast type II fiber P0 increases 
were similar between treatments. The higher sensitivity of the type I 
fiber to T therapy agrees with the observation of Sinha-Hikim et al,12 
who reported type I fiber area to increase in response to T 
supplements at levels less than that required for type II fibers. 
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Interestingly, subjects that responded well to WK treatment showed 
significant increases in fiber diameter and P0 in slow and fast fibers, 
whereas with the MO paradigm, in addition to responders with 
adaptations in both fiber types, we observed partial responders with 
significant functional changes in fast but not slow fibers. This likely 
resulted from the lower response of slow fibers to MO treatment (Table 
1). Our results demonstrate that slow fibers respond better to a 
continuous cellular exposure to T, whereas with fast fibers a threshold 
level of T is required, but not a continuous exposure. The increased 
effectiveness of WK over MO treatment for the type I fiber might not 
have been due to the pattern of administration, but rather to the 
different cumulative T dosage over the 5 months. An explanation for 
this fiber type difference is not readily apparent, but it might result 
from differences in receptor sensitivity and/or half-life of the cellular 
responses to T.10 To our knowledge, fiber type differences in T receptor 
sensitivity or response to hormone have not been studied. 
Our data suggest that the cellular improvements in P0 and peak 
power with T replacement were largely dependent upon the increase in 
fiber size. Thus, for the most part (an exception being the effect of WK 
on fast fibers, and for subject WK 3 both fiber types), there was no 
increase in relative force (kN/m2). As expected, the PL group, with the 
exception of a reduced type II fiber diameter and specific force, 
showed no change in slow or fast fiber function. The fast fiber-specific 
force increased due to the fiber atrophy. Although the cause of the 
fiber atrophy in the PL group is unknown, it could be a result of 
changes with aging over the 5-month period.22 Fiber stiffness (E0), an 
indicator of the number of cross-bridges, did not change with either 
WK or MO treatment. However, the P0/E0 ratio did significantly 
increase with WK in the slow type I fiber, which suggests an increase 
in the force per cross-bridge in this fiber. This adaptation should result 
in an increased relative force that increased, but not significantly. 
Thus, we conclude that any increase in force per cross-bridge with T 
treatment was relatively unimportant compared to the force increase 
due to the larger fiber size. 
Importantly, there were no changes in any kinetic parameter 
because neither V0 nor the ktr was altered by T replacement. The Ca2+ 
sensitivity of activation, as reflected by the activation threshold, pCa50, 
and slope of the Ca2+-force relationship (Supplemental Table 2), was 
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unaltered as well. Additionally, there was no change in the curvature 
of the force-velocity relationship (a/P0 ratio) that could have increased 
peak power. These results suggest that the T therapy did not alter the 
kinetics of the cross-bridge cycle and that the observed increases in 
power (Figure 1) can be entirely attributed to the increased force. 
An explanation for individual differences in response to T 
replacement therapy is not known and may involve factors not studied 
here. One possibility is that the initial serum T level and the extent of 
its increase with therapy are important to whether or not therapy 
produces significant cell responses. Although our data support this 
hypothesis (Table 2), future studies powered to address this question 
are needed. The variability in subject response to T therapy could also 
result from monthly variations in serum T levels achieved in response 
to the 100-mg monthly dose. This seems unlikely because for all of the 
WK subjects there was very little variation around their 1- to 5-month 
average.11 Because there were no data on T therapy effects on single 
fibers, the study was powered based on the known treatment effects 
on leg extension strength. Significant increases with treatment in 
some of the subjects (responders) suggest that the study was 
adequately powered. Nonetheless, the possibility exists that we may 
have observed more responders if the number of observations per 
subject was increased. 
Although it is not clinically practical to base a T therapeutic 
regimen on the fiber type distribution of the individual, we believe 
these data suggest that similar whole-muscle functional benefits occur 
in response to cycled and standard continuous T administration by 
virtue of the similarity in the cellular-level responses observed in type 
II fibers. Older men generally have significant muscle atrophy with 
selective loss of the fast type II fiber,22 which is considerably more 
powerful than type I fibers. To prevent large losses in peak power with 
aging, it is important to reduce atrophy and loss of function in the type 
II fiber. In that regard, the MO paradigm is equally as effective as the 
WK paradigm with one-half the dose of T. 
In conclusion, our work demonstrates for the first time that the 
improvements in skeletal muscle function in older men after T 
replacement therapy are fiber-type dependent and restricted to 
increases in cell size, P0, and peak power, and that the degree of 
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change in each fiber type depends on the treatment paradigm selected 
weekly vs monthly. Specifically, we found that monthly T 
administration increased type II fiber function equally to weekly 
administration. Because type II fibers show the greatest atrophy and 
are most often lost with aging, the monthly paradigm of T 
administration affords equal gains in fiber power with half the dose of 
T as weekly administration. Overall, these results suggest that 
improvements in single fiber function in skeletal muscle are possible 
with both standard weekly T administration and a monthly paradigm. 
Future studies are needed to determine the mechanisms involved, 
such as the role of IGF-1, in mediating the functional changes in slow 
and fast fiber function. 
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Footnotes 
Abbreviations:  
CSA cross-sectional area 
E0 peak elastic modulus 
FL fiber length 
kN kilonewton 
ktr rate of tension development 
mN millinewton 
MO monthly 
P0 peak force 
pCa negative log of the Ca2+ concentration 
PL placebo 
V0 maximal unloaded shortening velocity 
WK weekly. 
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Supplemental Methods 
Testosterone assay. Serum testosterone was determined using The ADVIA Centaur Testosterone 
assay e x a c t l y  a s  d e s c r i b e d  b y  t h e  m a n u f a c t u r e r ( ) . I t  is a competitive immunoassay 
using direct chemiluminescent technology. Testosterone in the patient sample competes with 
acridinium ester- labeled testosterone in the Lite Reagent for a limited amount of polyclonal rabbit 
anti testosterone antibody bound to monoclonal mouse anti-rabbit antibody, which is coupled to 
paramagnetic particles in the solid phase. The assay uses testosterone releasing agent to release 
bound testosterone from the endogenous binding proteins in the sample. The system automatically 
performs the following steps : Dispenses 15 µL of sample and 50 µL of releasing agent into a cuvette; 
Washes the reagent probe with 100 µL of probe wash ; Dispenses 50 µL of Lite reagent and 300 µL 
of solid phase and incubates for 5.0 minutes at 37°C; Separates, aspirates, and washes the cuvettes with 
reagent water ; Dispenses 300 µL each of acid reagent and base reagent to initiate the chemiluminescent 
reaction. 
Supplemental Figure 1: Relationship between type II fiber diameter and peak Ca2+-activated force 
(P0) for weekly testosterone (WK) treatment 
Each symbol represents the results of a single vastus lateralis type II fiber for each subject where open 
squares are pre-treatment fibers and filled squares are post-treatment fibers. For subject WK 2 no type II 
pre-treatment fibers were studied. The gray shaded triangle and gray shaded circle are the mean pre- and 
post-treatment values for the placebo group, respectively. 
Supplemental Figure 2: Relationship between type II fiber diameter and peak Ca2+-activated force 
(P0) for monthly testosterone (MO) treatment 
Each symbol represents the results of a single vastus lateralis type II fiber for each subject where open 
squares are pre-treatment fibers and filled squares are post-treatment fibers. The gray shaded triangle and 
gray shaded circle are the mean pre- and post-treatment values for the placebo group, respectively. 
Subject MO 1 is not shown as no post-treatment fast fibers were isolated from this sample. 
 


 
 
Supplemental Table 1. Type I and II fiber peak power with weekly and monthly TE 
  
Absolute Peak Power Relative Peak Power 
 
Muscle uN*FL*s-1 uN*FL*s-1 kN*m-2*FL*s-1 kN*m-2*FL*s-1 
VL Type I Type II Type I Type II 
Placebo     
Pre 10.18 ± 0.53 (47) 46.18 ± 2.71 (48) 1.31 ± 0.03 (47) 6.99 ± 0.34 (48) 
Post 10.72 ± 0.65 (53) 45.53 ± 3.10 (37) 1.39 ± 0.05 (53)  8.28 ± 0.63 (37)† 
% difference 5 -1 6 18 
Weekly     
Pre 
Post 
10.40 ± 0.46 (49) 
  14.62 ± 1.20 (44)** 
51.23 ± 4.29 (16) 
 65.99 ± 4.77 (41)† 
1.25 ± 0.05 (49) 
1.25 ± 0.03 (44) 
6.51 ± 0.37 (16) 
7.60 ± 0.44 (41) 
% difference 41 29 0 17 
Monthly     
Pre 8.43 ± 0.26 (68)* 47.12 ± 3.24 (35) 1.33 ± 0.04 (68) 8.41± 0.50 (35)* 
Post   9.53 ± 0.39 (58)**  54.22 ± 2.36 (27)† 1.36 ± 0.04 (58) 8.31 ± 0.52 (27) 
% difference 13 15 2 -1 
Values represent means ± SE; VL = vastus lateralis muscle; FL = fiber length; Weekly group received testosterone (TE) weekly for five 
months; Monthly group received TE weekly during months 1, 3 and 5. 
**Significant difference (p < 0.05) between pre and post means for a given group 
*Significant difference (p < 0.05) between placebo pre means and subject pre means 
†
Significantly different (p < 0.10) between pre and post mean for a given group 
 
 
Supplemental Table 2. Calcium sensitivity of slow type I and fast type II fibers 
 
Condition Activation Threshold pCa50 N1 N2 
 Pre Post Pre Post Pre Post Pre Post 
Weekly (WK) 
Type I 6.58 ± 0.02 6.57 ± 0.01 5.72 ± 0.01 5.70 ± 0.01 2.10 ± 0.09 2.14 ± 0.07 2.84 ± 0.06 2.80 ± 0.06 
Type II 6.46 ± 0.06 6.53 ± 0.03 5.92 ± 0.04 5.86 ± 0.01 1.85 ± 0.20 2.13 ± 0.11 4.68 ± 0.72 3.89 ± 0.21 
Monthly (MO) 
Type I 6.53 ± 0.01 6.59 ± 0.02 5.87 ± 0.05 5.79 ± 0.02 1.85 ± 0.07 2.00 ± 0.07 3.32 ± 0.07 3.04 ± 0.08 
Type II 6.54 ± 0.10 6.55 ± 0.09 5.90 ± 0.01 5.92 ± 0.01 1.91 ± 0.11 1.92 ± 0.09 4.34 ± 0.55 5.36 ± 0.85 
All data are pCa units (-log of Ca
2+ concentration) expressed as means ± SE; WK type I fibers pre treatment n = 30, post n = 37; WK type II fibers 
pre treatment n= 7, post n = 15; MO type I fibers pre treatment n = 50, post n = 43; MO type II fibers pre treatment n = 7, post n = 14; Activation 
Threshold is Ca
2+ that just elicits force, pCa50 equals –log of Ca
2+ concentration that elicits 50% of peak tension; N1 and N2 are slope of Hill plot 
for values greater than and less than half-maximal activation, respectively. 
